Ditch Labs Inc. Appoints Peter Bloch as Chairman of the Board of Directors

MONTREAL, QC, February 11, 2025 — Ditch Labs Inc., a pioneering life sciences company dedicated to revolutionizing nicotine addiction treatment through innovative solutions like the DitchPen®, is proud to announce the appointment of Peter Bloch as Chairman of the Board of Directors. With his extensive experience in both medical devices and therapeutics, Peter Bloch brings a wealth of expertise to guide Ditch Labs as it prepares to achieve major value-creating milestones, including a pivotal comparative bioavailability study unlocking commercialization in the United Kingdom in 2026, and upcoming clinical trials in the United States.

Peter Bloch is a seasoned executive with a remarkable career in the life sciences and medical technology sectors. Notably, as Chief Executive Officer and Chairman at Bionik Labs he led the company from an incubator to a US listed company with sales on four continents.. He has an extensive track record of leading and scaling MedTech and Biotech companies, securing over $100 million in funding through venture capital, IPOs, and strategic partnerships. He has successfully guided multiple companies from concept to commercialization and exit, leveraging his expertise in global growth, revenue expansion, and profitability.

“Ditch Labs is at a turning point, with clinical trials underway and commercialization on the horizon,” said Laurent Laferriere, Co-Founder and CEO of Ditch Labs. “Our device and mobile app are ready, and we are eager to enter significant markets. Peter’s leadership and deep expertise in scaling MedTech companies will be invaluable as we navigate this next phase. His strategic insight will help ensure we successfully navigate the complexities of bringing a medically approved, safe, and effective solution to the millions of smokers and vapers seeking a better way to quit.”

As Chairman of the Board, Mr. Bloch will work closely with Ditch Labs’ executive team to advance its strategic objectives, oversee governance, and strengthen its position as a leader in the nicotine cessation market.

“I am excited to join Ditch Labs and contribute to a product that has the potential to impact the lives of over a billion people worldwide,” said Peter Bloch. “Rarely do we have the chance to make such a profound impact in healthcare, and I look forward to working with the team to deliver meaningful change for individuals struggling with smoking or vaping addiction globally.”

Ditch Labs continues to innovate at the intersection of health and technology, with its flagship product, the DitchPen®, leveraging precise dosing and automated reduction to provide a personalized and gradual cessation experience. With Peter Bloch at the helm of its Board of Directors, the company is determined to advance its vision of a healthier, nicotine-free future.

About Ditch Labs Inc.:

Ditch Labs is a Montreal-based life sciences company developing innovative solutions for smoking and vaping cessation. Its flagship product, the DitchPen®, combines medical-grade nicotine replacement therapy with a user-friendly digital app to deliver a personalized, automated cessation program. Founded by a team of entrepreneurs and healthcare professionals, Ditch Labs is committed to empowering individuals to take control of their health and live nicotine-free lives.

Ditch Labs Inc. Acquires Enovap SAS, Expanding its Footprint in the Global Nicotine Addiction Market

Montreal, Canada – December 7, 2023 – Ditch Labs Inc., a leading innovator in the field of nicotine addiction treatment, today announced the strategic acquisition of key assets from Enovap SAS, a French company known for its advanced nicotine delivery solutions. This acquisition marks a significant step in Ditch Labs’ journey to reshape the landscape of nicotine addiction treatments.

The acquisition of a comprehensive portfolio of patents from Enovap SAS, granted in 15 countries, significantly enhances Ditch Labs' intellectual property holdings and positions the company as a key innovator in the inhalation and respiratory sector. This strategic move goes beyond addressing nicotine addiction, expanding Ditch Labs' reach in developing advanced inhalation technologies. Moreover, this expansion not only strengthens Ditch Labs’ role in the nicotine addiction treatment market valued at $40 billion but also unlocks opportunities for licensing and strategic partnerships, essential for driving forward innovation in healthcare solutions on a global scale.

Laurent Laferriere, CEO of Ditch Labs, shared his enthusiasm for the acquisition: "This acquisition from Enovap is a testament to our commitment to being at the forefront of innovation in the nicotine addiction treatment space. By integrating these key assets, we are ready to expand our reach and deliver cutting-edge solutions that cater to the unique needs of individuals battling nicotine addiction."

Ditch Labs' approach to nicotine addiction treatment uniquely combines a smart medical nicotine vaporizer with a comprehensive therapeutic mobile app. This integrated solution aims to revolutionize the treatment landscape by offering a more effective and personalized approach to smoking cessation and nicotine dependence.

The cost of the acquisition remains undisclosed.

Ditch Labs Wins The Jury’s First Prize Following Acfas Competition’s 6th Edition

MONTREAL, QC/March, 2022 – The 6th edition of Acfas competition occurred on March 29th and was broadcasted live.

Following the event, the research team of Ditch Labs, Inc. led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais, Pharmacologist Mehdi El Hassani, Researcher in Psychology Éric Hanigan and Financial Analyst Naïl Sousa Cordeiro as part of the 6 finalist teams, wins the jury’s first prize. The prize includes a value of more than $22,000 in consulting and scholarship services. The company sincerely thanks Acfas and the jury for the opportunity to participate.

“We couldn’t be happier following the performance of our research team which includes Christelle Luce, P.h.D, Olivier Bourbonnais, Mehdi El Hassani, Éric Hanigan and Naïl Sousa Cordeiro during yesterday’s competition of Acfas. It is an honor to have participated and to be the winning team of the jury’s first prize! Congratulations to all the participants and thanks to the jury for their time and support.” - Ditch Labs, Public Statement

Ditch Labs Appoints Moishe Liberman, MD, PhD, FACS, FRCSC, as Chief Medical Officer

MONTREAL, QC/March 23, 2022 – Ditch Labs, Inc. is honored to appoint Dr. Moishe Liberman as Chief Medical Officer (CMO). Dr. Liberman is a minimally invasive thoracic surgeon trained at Harvard University who has run over 40 clinical trials at the CHUM Research Center over the last 13 years in Thoracic Surgical Oncology.

“It is a pleasure to be joining Ditch Labs’ stellar team to participate in developing such an innovative and revolutionary system. Seeing firsthand the consequences of tobacco use and the unmet needs caused by the lack of effective treatments, I am deeply motivated to contribute to the new paradigm that Ditch is creating in smoking cessation.”

- Dr. Moishe Liberman, Chief Medical Officer at Ditch Labs

Some of the responsibilities assumed by Dr. Liberman will be strategic supervision of the company’s medical and clinical affairs, including aiding in recruitment of various partners, establishing the corporation’s scientific advisory board and key opinion leadership and supporting in the design, planning and execution of clinical trials.

“Since the beginning, one of Ditch’s missions is to bring together the brightest minds to solve the leading cause of preventable death. The appointment of Dr. Liberman as CMO marks an important step in building a solid executive team, bringing us closer to reaching our first clinical milestone by the end of the year.”

- Laurent Laferrière, Co-Founder and CEO at Ditch Labs

As Ditch prepares for its First In Human study, the company looks forward to working alongside such a renowned physician with direct access to valuable resources and patients in dire need of effective smoking cessation treatments.

Ditch Labs Announced As Finalist Of ACFAS Competition’s 6th Edition

MONTREAL, QC/March, 2022 – Led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais, Pharmacologist Mehdi El Hassani, Researcher in Psychology Éric Hanigan, Financial Analyst Naïl Sousa Cordeiro and Medical Devices Consultant Jean-Pierre Desmarais, Ditch Labs, Inc. becomes finalist of the renowned Génies en affaires competition which will occur live on Facebook on March 29th, 2022. The event will include a 5-minute question period following an 80-second sales pitch and a vote from the public to choose the winners.

Ditch Receives $350,000 Of Funding From Québec’s Ministère de l’Économie et de l’Innovation (MEI), In Collaboration With MEDTEQ+ And PromptInnov

MONTREAL, QC/February, 2022 – Ditch Labs, Inc. receives $350,000 of additional funding from the MEI. The funding operation is led by MEDTEQ+ and PromptInnov as holders of the HI_DOS program which aims to support the security certification, regulatory approval processes and interoperability activities of Quebec companies wishing to market connected objects in the health sector.

Ditch Partners With The CRIQ, Investissement Québec's World-Renowned Laboratory, For Nonclinical Testing

MONTREAL, QC/January, 2022 – Ditch Labs, Inc.’s partnership with the CRIQ led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais and Pharmacologist Mehdi El Hassani, will serve the objective of characterizing the aerosol generated by the DitchPen™. The company intends to present a toxicology report to the FDA and Health Canada in order to receive a Clinical Trial Authorization (Health Canada) and an Investigational New Drug approval (FDA).

Ditch Completes Successful Integration And Testing Of Its Second-Generation Alpha Product, Ready For Nonclinical Testing

MONTREAL, QC/January, 2022 – Ditch Labs, Inc. completing the successful integration and testing of its second-generation alpha product marks a green status for the upcoming nonclinical testing. The new alpha prototypes led by Co-Founder and CTO Olivier Bourbonnais and Hardware Expert François Bélanger include newer designs optimized for manufacturing along with a more effective mechanism allowing the device to be more accurate.

Ditch Labs Receives Funding From The National Research Council's IRAP Program

MONTREAL, QC/December, 2021 – Following the partnership between Ditch Labs, Inc. and the CRIM along with professional recommendations, the company’s application for the non-dilutive funding of the National Research Council’s IRAP program is now approved. These additional funds will finance the fees of the CRIM researchers.

Ditch Partners Up With The Computer Research Institute of Montréal (CRIM) To Develop Its Treatment Algorithms

MONTREAL, QC/December, 2021 – The partnership of Ditch Labs, Inc. with the CRIM to develop its treatment algorithms led by Research Director and Partner Christelle Luce, Co-Founder and CTO Olivier Bourbonnais, Software Director Étienne Bélanger and Researcher Gabrielle Toupin, will strengthen the cybersecurity of its solutions and allow the company to develop algorithms based on the data it collects from the DitchPen™ and from the DitchApp™, among other important aspects.